Treatment for Feline Infectious Peritonitis (“FIP”): GS-441524

What is FIP?

Feline Infectious Peritonitis (FIP) is a severe and often fatal viral disease caused by feline coronavirus. The inflammation caused by FIP predominantly affects critical organs such as the liver, kidneys, and brain, but can also damage other areas like the eyes and intestines.

FIP is considered one of the most devastating diseases in cats, particularly because it can progress rapidly and has been historically viewed as untreatable.

How Does FIP Affect Cats?

FIP often shows through a variety of symptoms, which can vary depending on the form of the disease. Symptoms range from abdominal swelling or difficulty breathing caused by accumulation of fluid in the abdomen or chest, or fever, weight loss, lethargy and vision impairment.

The disease is most commonly diagnosed in young cats under the age of 2, mostly those living in multi-cat environments, where the virus is more likely to spread. Adult cats are not immune and can also be infected. FIP rapidly progresses to organ failure if left untreated, which is often fatal.

Before viable antiviral treatments, FIP was almost universally fatal, with supportive care being the only available option. Fortunately, newer treatments like GS-441524 have revolutionized FIP management, offering many cats the best chance at recovery.

Treatment for FIP: GS-441524

What is GS-441524?

GS-441524 is an antiviral drug that has emerged as a groundbreaking treatment for FIP. By targeting the feline coronavirus, GS-441524 helps stop the spread of the virus within the body and gives the cat’s immune system the ability to fight the infection. GS-441524 is a metabolite of a different antiviral drug called remdesivir, which has also been used to treat FIP in some case studies. Remdesivir is currently available in the US as an injectable but is extremely expensive and is not a good option for most pet owners. 

How is GS-441524 Used?

GS-441524 is typically administered in the form of an oral liquid but can also be compounded into other oral formulations. The duration of treatment can last up to 12 weeks depending on the severity of the FIP and the cat’s response to the medication. Most cats begin to show signs of improvement within 1-2 weeks of starting treatment, and full recovery can be achieved when the full course is completed.

At Northwest Compounders, GS-441524 is compounded into an oral liquid, easing administration for owners, allowing them to treat their cats comfortably at home.Compounded liquids can be flavored with a pet friendly flavor like chicken, beef or fish to improve palatability of the medication. 

If you suspect your cat has FIP or have been given a diagnosis, contact your veterinarian to discuss the possibility of starting GS-441524 treatment. Starting treatment immediately after a diagnosis is made can help improve the chances of a positive treatment outcome.

If you are a veterinarian interested in providing GS-441524 for your patients, you can now conveniently order online using the link HERE. If you have questions about FIP treatment with GS-441524, please call our pharmacy today to speak with one of our pharmacists (503) 352-3811

Sarah Muse

Marketing Specialist

B.S. Integrated Marketing Communications, University of Mississippi, 2021

Team Member since September 2024

Joshua Reed, CPhT

Hazardous Compounding Lead

Team Member since April 2020

Paul Donald, CPhT

Quality Control Lead

Team Member since July 2020

Julian Sonnenburg, PharmD

compounding pharmacist

Doctor of Pharmacy, Pacific University, 2020

B.S. Food Science and Technology, Oregon State University, 2013

Northwest Compounders Intern, 2019

Team Member since June 2024

Regina Karpa, PharmD

Compounding pharmacist

Doctor of Pharmacy, University of Southern California, 2007

B.S. Psychobiology, University of California of Los Angeles, 2003

Certificate in Veterinary Compounding

Certificate in Personalized Dermatology

Certificate in Personalized Hormone Replacement Therapy

Certificate in CORE Compounding Training

Team Member since April 2024

Announcement: Our pharmacy will be closing early at 6:30 pm on Tuesday, Dec. 31 and closed on Wednesday, Jan. 1 for New Year’s Day. Please schedule your next prescription or refill request with this in mind.

Announcement:  Our pharmacy will be closing early at 2:00 pm on Tuesday, Dec. 24 and closed on Wednesday, Dec. 25 in observance of Christmas. Please schedule your next prescription or refill request with this in mind.

William Kenward, CPhT

project manager

Team member since 2015

Chris Gralian, CPhT

Quality Control Lead

Team member since 2019

Rose Hood, CPhT

Quality Control Lead

Team member since 2016

Matthew Peterson, CPhT

Quality Control Lead

Team member since 2016

Helen Dubintsov, CPhT

Quality Control Lead

Team member since 2016

Shannon Kimball, PharmD

Compounding Pharmacist

Doctor of Pharmacy, Pacific University 2022

B.S. Biohealth Science, Oregon State University 2019

Team member since 2018

Mark Liu, PharmD

Compounding Pharmacist

Doctor of Pharmacy, Oregon State University 2005

BA Biology, Reed College 1998

12 years of retail experience

Team member since January 2017

Jill Snyder, RPh

Compounding Pharmacist

B.S. Pharm. 1994 Oregon State University

5 years of retail pharmacy experience

17 years of long-term care experience

Certificate in Veterinary Pharmacy, 2016

Team member since May 2016

Scott Williams, RPh

Compounding Pharmacist

B.S. Pharm. 1992 Oregon State University

24 years of experience in Retail Pharmacy

Team member since November 2015

Certificates in CPR, Diabetes Management, Immunization, Cholesterol Management and Medication Therapy Management

Bob Templin, RPh

compounding pharmacist

B.S. Pharm. 1976 Oregon State University

Certificate in Veterinary Pharmacy, 2019

Over 37 years of pharmacy experience

Over 33 years as a Pharmacy Manager

Team member since February 2013

Megan Gustafson, PharmD

Director of Training

Doctor of Pharmacy, Oregon State University 2021

B.S. Bio-Health Sciences, Oregon State University 2017

Team member since 2016

Sam Llona, PharmD

Director of Sterile Operations

Doctor of Pharmacy, Creighton University 2019

B.S. Biology, Santa Clara University

Certificate in Aseptic Compounding, PCCA 2014

Certificate in Human Compounding, PCCA, 2016

Certificate in Veterinary Compounding, PCCA, 2017

Team member since September 2019

Vivian Pham, PharmD

Senior Operations Manager,
Director of Accounting

Doctor of Pharmacy, Oregon State University 2016

Has worked as a technician, bookkeeper, pharmacy intern and now pharmacist for Northwest Compounders

Team member since May 2008

Jessie Vo, PharmD

Pharmacy Manager,
Director of Quality Assurance

Doctor of Pharmacy, Pacific University 2011

Preceptor for Pacific University SOP, Oregon State SOP

Team member since January 2006

Luke Eilers, PharmD

Chief Executive Officer

Doctor of Pharmacy, Pacific University 2014

B.S. General Science, Oregon State University 2011

Certificate in Veterinary Pharmacy, 2018

Certificate in Basic Compounding, PCCA 2014

Certificate in Aseptic Compounding, PCCA 2014

Preceptor for Pacific University SOP, Oregon State SOP

Team member since October 2005

Tom Eilers, RPh

Founder, Chairman

B.S. Pharm. 1976 Oregon State University

Founder, Northwest Compounders 2005

Member, International Academy of Compounding Pharmacists

Member, PCCA (Professional Compounding Centers of America)

Certificate in Basic Compounding Techniques, PCCA, 2001

Certificate in Aseptic Compounding, PCCA 2005

Preceptor for Pacific University SOP, Oregon State SOP, Washington State SOP

Filter products by drug name.